Journey Medical Corporati... (DERM)
3.73
-0.05 (-1.32%)
At close: Jan 14, 2025, 3:59 PM
3.73
0.00%
After-hours Jan 14, 2025, 04:00 PM EST
undefined% (undefined)
| Bid | 3.54 |
| Market Cap | 77.92M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.92 |
| PE Ratio (ttm) | -4.05 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 4.99 |
| Volume | 68,126 |
| Avg. Volume (20D) | 112,019 |
| Open | 3.73 |
| Previous Close | 3.78 |
| Day's Range | 3.54 - 3.84 |
| 52-Week Range | 2.85 - 6.89 |
| Beta | undefined |
About DERM
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; X...
Sector Healthcare
IPO Date Nov 12, 2021
Employees 41
Stock Exchange NASDAQ
Ticker Symbol DERM
Website https://journeymedicalcorp.com
Analyst Forecast
According to 3 analyst ratings, the average rating for DERM stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 141.29% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Journey Medical Corporation is scheduled to release its earnings on Mar 20, 2025,
during market hours.
Analysts project revenue of $14.21M, reflecting a -6.86% YoY shrinking and earnings per share of -0.15, making a 25.00% increase YoY.
Analysts project revenue of $14.21M, reflecting a -6.86% YoY shrinking and earnings per share of -0.15, making a 25.00% increase YoY.
5 months ago ·
Source
+14.22%
Journey Medical shares are trading higher after th...
Unlock content with
Pro Subscription
9 months ago ·
Source
-13.61%
Journey Medical shares are trading lower. The company reported Q4 financial results.
